SLC5A2 and diabetes mellitus: The global DISCOVER prospective observational study, encompassing 37 countries, reported a substantial increase in the use of SGLT2-is and GLP-1RAs between 2014 and 2016, with median usage reaching 19.4% of people with diabetes by 2016 [14].